The European Medicines Agency (EMA) has introduced email notification functionality in the Clinical Trials Information System (CTIS), enabling trial sponsors, researchers, and regulatory stakeholders to receive real-time updates on clinical trial submissions and status changes. This enhancement aims to streamline communication and reduce manual monitoring of the centralised platform that oversees all European Union clinical trials.
Key takeaways
- EMA rolled out email notification subscriptions in CTIS, the EU’s centralised clinical trial information platform
- Users can now customise alerts for trial submissions, amendments, and regulatory decisions without manual platform checks
- The feature reduces administrative burden for trial sponsors and improves real-time transparency across the clinical trial ecosystem
CTIS Streamlines EU Clinical Trial Management
Email notifications reduce monitoring burden for trial stakeholders
Source: EMA CTIS Enhancement Overview, 2026 | Georgian Medical Journal News
Centralised System Overhauls Clinical Trial Transparency
CTIS replaced national trial registries across EU member states in 2024, creating a single, transparent repository where all trial data—from initial assessment through completion—are publicly accessible. According to the EMA’s Clinical Trials Information System overview, the platform consolidates applications from all 27 EU member states plus the European Economic Area. The new email notification feature builds on this foundation, allowing users to track developments without requiring constant manual review of the platform.
Trial sponsors, principal investigators, and regulatory affairs professionals previously relied on periodic manual checks to monitor application status and regulatory decisions. Email subscriptions now eliminate this inefficiency, delivering updates directly to designated contacts as events occur.
Customisable Alerts Enhance Workflow Efficiency
Users can configure notifications to target specific trial milestones: protocol submissions, ethics committee assessments, competent authority decisions, and post-approval amendments. This granular subscription model—detailed in the EMA’s notification announcement—allows stakeholders to filter alerts by relevance, reducing information overload while ensuring critical updates reach the right team members immediately.
The system integrates directly with CTIS user accounts, enabling multi-user organisations to assign notifications to different departments. Regulatory teams, for example, may receive competent authority decision notifications, while research coordinators track site-level communications and safety updates.
Implications for the European Clinical Trial Ecosystem
The EMA’s email notification feature transforms CTIS from a repository into an active communication channel, reducing administrative friction and accelerating trial transparency across the EU clinical research enterprise.
— European Medicines Agency, Clinical Trials Information System Enhancement (2026)
This upgrade reflects the EMA’s commitment to modernising clinical trial oversight. By automating routine status communications, the system frees trial teams to focus on science rather than administrative tracking. Smaller contract research organisations (CROs) and academic institutions—which often lack dedicated regulatory monitoring staff—particularly benefit from this streamlined workflow. For detailed guidance on CTIS usage, researchers can consult the EMA’s Clinical Trials resource hub.
Additionally, the notification system enhances transparency for ethics committees and member state regulators, who can now align their own communications with system-generated alerts. This creates a more coordinated regulatory environment and reduces the risk of miscommunication or missed deadlines. Learn more about clinical trial policy updates in our Clinical Updates section.
What this means
Frequently asked questions
How do I enable email notifications in CTIS?
Users log into their CTIS account and navigate to notification preferences, where they can select which trial milestones (submissions, assessments, decisions) trigger email alerts. Configuration is role-based, allowing sponsors to assign different notification types to team members according to their responsibilities.
Will email notifications delay trial timelines?
No. Notifications are generated automatically when system events occur—they do not affect processing timelines. Instead, they ensure stakeholders are informed in real time, potentially accelerating responses to requests or amendments.
Are email notifications mandatory?
Notifications are optional. Users can subscribe selectively or disable them entirely. However, the EMA recommends subscription for at least competent authority decisions and safety-critical updates to ensure no regulatory communications are missed.
As the EMA continues to optimise CTIS functionality, additional notification categories—such as safety alerts or recruitment milestones—may be added. Sponsors and researchers should review their notification settings regularly and ensure contact information is current to avoid missing critical updates. This feature represents a significant step toward a more interactive, responsive clinical trial environment across Europe. For more on health policy and regulatory advances, explore our Health Policy category.
Source: Are you running clinical trials? You can now activate e-mail notifications in CTIS, Danish Medicines Agency / EMA, 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
